CCDC21 Inhibitors
CCDC21 Inhibitors are a class of chemical compounds that decrease the functional activity of CCDC21 through a variety of biochemical pathways. Compounds such as Rapamycin, LY 294002, Wortmannin, and Triciribine target key signaling pathways like mTOR, PI3K, and Akt, which are critical for processes including protein synthesis, cell growth, and survival. If CCDC21 is involved in these processes, the inhibition of these pathways by these compounds would result in a diminished functional activity of CCDC21, due to the reduced cellular context in which CCDC21 operates or the disruption of signaling cascades it may be part of. Similarly, SB 203580 and PD 98059, by targeting p38 MAPK and MEK respectively, could interfere with phosphorylation events or signaling mechanisms that regulate CCDC21's activity. Bafilomycin A1 and Thapsigargin, by affecting endosomal/lysosomal acidification and calciumhomeostasis, could indirectly inhibit CCDC21 if its function involves trafficking within these organelles or is calcium-dependent.
The functional regulation of CCDC21 is also potentially influenced by compounds that disrupt kinase signaling pathways, exemplified by Gö 6983 and SP600125, which inhibit PKC and JNK respectively. These inhibitors could lead to a reduction in CCDC21 activity by preventing the phosphorylation of proteins within signaling pathways that CCDC21 may be involved in, particularly those associated with stress responses or apoptosis. Alsterpaullone, as a cyclin-dependent kinase inhibitor, might diminish CCDC21's role in cell cycle progression, while U0126's disruption of the ERK pathway could similarly lead to decreased CCDC21 activity through its involvement in signal transduction. Collectively, these CCDC21 inhibitors, by targeting distinct but potentially interconnected signaling pathways and cellular processes, serve to indirectly impede the functional activity of CCDC21.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
A mTOR inhibitor, Rapamycin reduces protein synthesis and cell proliferation. If CCDC21 is involved in these cellular processes, Rapamycin's inhibition of mTOR could indirectly diminish CCDC21's functional activity by reducing the cellular context in which CCDC21 operates. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
As a p38 MAPK inhibitor, SB 203580 disrupts inflammatory responses and differentiation pathways. Inhibition of p38 MAPK may lead to reduced phosphorylation of proteins downstream in the pathway, which could include CCDC21 if it is phosphorylated as part of its functional regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, LY 294002 could indirectly decrease CCDC21 activity by preventing PI3K-mediated signaling pathways that may be necessary for CCDC21's function in cell growth and survival. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, Wortmannin, could lead to the diminishment of CCDC21 activity by inhibiting the PI3K pathway, potentially affecting CCDC21's role in cellular processes such as trafficking or signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
This MEK inhibitor could indirectly inhibit CCDC21 by disrupting the ERK pathway, which may influence CCDC21's function if it is involved in signal transduction mechanisms that depend on this pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
An Akt inhibitor, Triciribine may indirectly diminish CCDC21's activity by inhibiting Akt-dependent signaling pathways, potentially impacting CCDC21's role in processes like cell survival and metabolism. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor, PD 98059 could reduce CCDC21 activity by interfering with the MEK/ERK signaling pathway, which may be a part of the regulatory mechanism for CCDC21's function. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
As an inhibitor of the V-ATPase, Bafilomycin A1 could lead to diminished CCDC21 activity by altering endosomal and lysosomal acidification, which may affect the trafficking or function of CCDC21. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A PKC inhibitor, Gö 6983 may diminish CCDC21 activity by disrupting protein kinase C-mediated signaling pathways that could be regulating CCDC21's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 could reduce CCDC21's activity by preventing JNK-mediated signaling processes which CCDC21 may be involved in, particularly if it plays a role in stress or apoptosis pathways. | ||||||